{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:44:58Z","timestamp":1793994298993,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.esmoop.2024.104086","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T21:51:49Z","timestamp":1734558709000},"page":"104086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Globalization of clinical trials in oncology: a worldwide quantitative analysis"],"prefix":"10.1016","volume":"10","author":[{"given":"F.","family":"Izarn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Besle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Allignet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.104086_bib1","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.34455","article-title":"Associations between geography, decision-making style, and interest in cancer clinical trial participation","volume":"128","author":"Caston","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.104086_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/djaa155","article-title":"\u201cWhen offered to participate\u201d: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials","volume":"113","author":"Unger","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.104086_bib3","series-title":"Impure Science: AIDS, Activism, and the Politics of Knowledge","author":"Epstein","year":"1996"},{"key":"10.1016\/j.esmoop.2024.104086_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd2441","article-title":"Trends in the globalization of clinical trials","volume":"7","author":"Thiers","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.esmoop.2024.104086_bib5","author":"Williams"},{"key":"10.1016\/j.esmoop.2024.104086_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13063-017-2025-1","article-title":"Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011-2013","volume":"18","author":"Jeong","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.esmoop.2024.104086_bib7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(10)61152-X","article-title":"Expansion of cancer care and control in countries of low and middle income: a call to action","volume":"376","author":"Farmer","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.104086_bib8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1378\/chest.15-0706","article-title":"Institutional review boards","volume":"148","author":"Grady","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.esmoop.2024.104086_bib9","series-title":"International Ethical Guidelines for Health-related Research Involving Humans","year":"2016"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104086_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.7075","article-title":"Evaluation of drug trials in high-, middle-, and low-income countries and local commercial availability of newly approved drugs","volume":"4","author":"Miller","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2024.104086_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4254","article-title":"Protections for clinical trials in low and middle income countries need strengthening not weakening","volume":"349","author":"Dal-R\u00e9","year":"2014","journal-title":"Br Med J"},{"key":"10.1016\/j.esmoop.2024.104086_bib12","article-title":"Global migration of clinical research during the era of trial registration","volume":"13","author":"Drain","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2024.104086_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2024.104086_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001612","article-title":"Building research capacity in Africa: equity and global health collaborations","volume":"11","author":"Chu","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.esmoop.2024.104086_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012332","article-title":"Health research capacity development in low and middle income countries: reality or rhetoric? A systematic meta-narrative review of the qualitative literature","volume":"7","author":"Franzen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.esmoop.2024.104086_bib16","series-title":"Technical Report: Pricing of Cancer Medicines and its Impacts: A Comprehensive Technical Report for the World Health Assembly Resolution 70.12: Operative Paragraph 2.9 on Pricing Approaches and Their Impacts on Availability and Affordability of Medicines","year":"2018"},{"key":"10.1016\/j.esmoop.2024.104086_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaoncol.2020.7478","article-title":"An analysis of contemporary oncology randomized clinical trials from low\/middle-income vs high-income countries","volume":"7","author":"Wells","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.104086_bib18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0140-6736(13)61046-6","article-title":"Mapping of available health research and development data: what\u2019s there, what\u2019s missing, and what role is there for a global observatory?","volume":"382","author":"R\u00f8ttingen","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.104086_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.104086_bib21","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.esmoop.2024.104086_bib22","series-title":"Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups","year":"2022"},{"key":"10.1016\/j.esmoop.2024.104086_bib23","article-title":"Future of cancer treatment guidelines: integrating real-world insights for equitable cancer care","volume":"8","author":"Miksad","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.esmoop.2024.104086_bib24","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","article-title":"Evolution of drug regulations and regulatory innovation for anticancer drugs in China","volume":"12","author":"Liu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.esmoop.2024.104086_bib25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(13)62387-9","article-title":"Building clinical research capacity in China: the National Clinical Research Centres","volume":"383","author":"Yang","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.104086_bib26","first-page":"288","article-title":"The public-private partnerships in\u00a0healthcare sector in China","volume":"9","author":"Liu","year":"2023","journal-title":"Chronic Dis Transl Med"},{"key":"10.1016\/j.esmoop.2024.104086_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1745-6215-9-22","article-title":"An assessment of the quality of randomised controlled trials conducted in China","volume":"9","author":"Zhang","year":"2008","journal-title":"Trials"},{"key":"10.1016\/j.esmoop.2024.104086_bib28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.104086_bib29","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/annonc\/mdt326","article-title":"The role of generic medicines and biosimilars in oncology in low-income countries","volume":"24","author":"Renner","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104086_bib30","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/pharmaceutics14122721","article-title":"Biosimilars in oncology: latest trends and regulatory status","volume":"14","author":"Joshi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.esmoop.2024.104086_bib31","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/annonc\/mdt326","article-title":"The role of generic medicines and biosimilars in oncology in low-income countries","volume":"24","author":"Renner","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104086_bib32","first-page":"1","article-title":"Increasing inclusiveness of patient-centric clinical evidence generation in oncology: real-world data and clinical trials","volume":"42","author":"Benbow","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.esmoop.2024.104086_bib33","series-title":"Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups","year":"2022"},{"key":"10.1016\/j.esmoop.2024.104086_bib34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41597-020-00780-z","article-title":"Obstacles to the reuse of study metadata in ClinicalTrials.gov","volume":"7","author":"Miron","year":"2020","journal-title":"Sci Data"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:55:26Z","timestamp":1737766526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2059702924018568"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104086","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Globalization of clinical trials in oncology: a worldwide quantitative analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104086"}}